Allogene Therapeutics (NASDAQ:ALLO) Trading 6.6% Higher

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) shares rose 6.6% on Monday . The stock traded as high as $3.10 and last traded at $3.08. Approximately 110,079 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 2,520,558 shares. The stock had previously closed at $2.89.

Analysts Set New Price Targets

ALLO has been the subject of several research reports. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a research report on Tuesday, March 19th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $10.00 target price on shares of Allogene Therapeutics in a research report on Friday, March 15th. JMP Securities reaffirmed a "market perform" rating on shares of Allogene Therapeutics in a research report on Friday, January 5th. Guggenheim cut Allogene Therapeutics from a "buy" rating to a "neutral" rating in a research report on Friday, January 5th. Finally, JPMorgan Chase & Co. reduced their target price on Allogene Therapeutics from $9.00 to $8.00 and set an "overweight" rating for the company in a research report on Tuesday, February 27th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $12.94.

Allogene Therapeutics Stock Down 1.7 %

The company has a market capitalization of $484.84 million, a P/E ratio of -1.41 and a beta of 0.81. The stock has a fifty day simple moving average of $4.32 and a 200-day simple moving average of $3.55.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.04. The company had revenue of $0.02 million during the quarter, compared to analysts' expectations of $0.05 million. Allogene Therapeutics had a negative return on equity of 53.76% and a negative net margin of 202,366.25%. Analysts predict that Allogene Therapeutics, Inc. will post -1.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. McGlone Suttner Wealth Management Inc. acquired a new stake in shares of Allogene Therapeutics in the fourth quarter valued at $27,000. Axxcess Wealth Management LLC acquired a new stake in shares of Allogene Therapeutics in the fourth quarter valued at $34,000. Aaron Wealth Advisors LLC acquired a new stake in shares of Allogene Therapeutics in the fourth quarter valued at $34,000. EP Wealth Advisors LLC acquired a new stake in shares of Allogene Therapeutics in the third quarter valued at $34,000. Finally, Victory Capital Management Inc. acquired a new stake in shares of Allogene Therapeutics in the third quarter valued at $37,000. 83.63% of the stock is owned by institutional investors.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).